BRIEF published on 07/09/2026 at 18:05, 1 month 14 days ago THX Pharma annonce sa trésorerie en juin 2026. Étude De Phase 3 Maladie De Batten Maladie De Niemann-Pick THX Pharma Position De Trésorerie
BRIEF published on 07/09/2026 at 18:05, 1 month 14 days ago THX Pharma maintains its financial stability as of June 30, 2026 Treasury Phase 3 TX01 THX Pharma Biocodex
BRIEF published on 07/09/2026 at 18:05, 1 month 14 days ago THX Pharma Announces June 2026 Cash Position Cash Position Phase 3 Study Batten Disease Niemann-Pick Disease THX Pharma
BRIEF published on 07/09/2026 at 18:05, 1 month 14 days ago THX Pharma maintient sa stabilité financière au 30 juin 2026 Trésorerie Phase 3 TX01 THX Pharma Biocodex
PRESS RELEASE published on 07/09/2026 at 18:00, 1 month 14 days ago THX Pharma Reports Cash Position as of June 30, 2026 THX Pharma (Theranexus) announces cash position of €17.5 million as of June 30, 2026. Biocodex funds clinical development costs for Batten-1 program. Positive milestones achieved in 2026 towards commercialization Cash Position Commercialization THX Pharma Biocodex Batten-1 Program
PRESS RELEASE published on 07/09/2026 at 18:00, 1 month 14 days ago THX Pharma publie sa position de trésorerie au 30 juin 2026 THX Pharma annonce sa trésorerie au 30 juin 2026 et les avancées majeures du premier semestre. Position financière solide pour la phase 3 de la maladie de Batten Trésorerie Position Financière Batten-1 Maladies Neurologiques Rares THX Pharma
BRIEF published on 06/23/2026 at 18:05, 2 months ago THX Pharma nomme Sophie Jacq Lapointe à son conseil d'administration Conseil D'administration Maladies Rares Stratégie Pharmaceutique THX Pharma Sophie Jacq Lapointe
BRIEF published on 06/23/2026 at 18:05, 2 months ago THX Pharma Appoints Sophie Jacq Lapointe to Board of Directors Board Of Directors Rare Diseases Pharmaceutical Strategy THX Pharma Sophie Jacq Lapointe
BRIEF published on 06/23/2026 at 18:05, 2 months ago THX Pharma Accueille Sophie Jacq Lapointe dans son Conseil d'administration Conseil D'administration Stratégie Pharmaceutique THX Pharma Commercialisation Internationale Sophie Jacq Lapointe
BRIEF published on 06/23/2026 at 18:05, 2 months ago THX Pharma Welcomes Sophie Jacq Lapointe to its Board of Directors Board Of Directors Pharmaceutical Strategy THX Pharma International Marketing Sophie Jacq Lapointe
Published on 08/22/2026 at 05:50, 1 day 17 hours ago Battery X Metals Provides Board of Directors Update
Published on 08/22/2026 at 04:55, 1 day 18 hours ago Vanta Announces Closing of First Tranche of Private Placement and Board of Directors Update
Published on 08/22/2026 at 00:30, 1 day 23 hours ago BioNxt Solutions Inc. Announces Closing of Extension of Convertible Debentures and Issuance of Warrants
Published on 08/21/2026 at 23:00, 2 days ago Tintina Mines Announces Voting Results from its Annual General and Special Meeting of Shareholders
Published on 08/21/2026 at 23:00, 2 days ago Silver Storm Announces $7.5 Million Non-Brokered Private Placement with Eric Sprott
Published on 08/21/2026 at 19:36, 2 days 4 hours ago EQS-Adhoc: KAP AG ANNOUNCES CHANGE IN SHAREHOLDER STRUCTURE
Published on 08/21/2026 at 19:11, 2 days 4 hours ago EQS-Adhoc: Marley Spoon Group SE: Discussions with Misfits Market as permanent US fulfillment agent
Published on 08/21/2026 at 18:14, 2 days 5 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/21/2026 at 17:27, 2 days 6 hours ago EQS-Adhoc: PSI Adjusts Its Forecast for Fiscal Year 2026 in Light of Economic Uncertainties in Europe
Published on 08/21/2026 at 16:30, 2 days 7 hours ago BL Networks (BLNWX) Details Major Global Infrastructure Expansion and Upgrades
Published on 08/18/2026 at 18:00, 5 days 5 hours ago KLARSEN : Nomonation Olivier Cornelis DG ITL et webinaire
Published on 08/18/2026 at 17:45, 5 days 6 hours ago Mise à disposition du rapport financier annuel 2025-26
